Key facts
- It has raised $20.3M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Korea Investment Partners, Mirae Asset Capital, Hana Ventures, STIC Ventures, Kiwoom Investment — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for S-Alpha Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for S-Alpha Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About S-Alpha Therapeutics
Developer of health applications and digital therapeutics designed to create a healthy and equitable society. The company offers treatment methods for disease areas including ophthalmology, neuropsychiatry, cancer, and immunology along with therapeutic devices and technologies and provides a digital approach for unmet medical needs, enabling patients to receive treatment for different diseases that are difficult to treat with current medical technology.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 20
- Website
- salphadtx.com/
- Ownership
- Privately Held (backing)
S-Alpha Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in S-Alpha Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on S-Alpha Therapeutics in its N-PORT filings yet. We sweep new filings monthly.